Lutathera® (lutetium Lu 177 dotatate) – New orphan drug approval
January 26, 2018 - The FDA announced the approval of Advanced Accelerator Applications’ Lutathera (lutetium Lu 177 dotatate), for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults.
Top